Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect and lyse melanoma. This study is to assess safety of a single intratumoural injection of the virus into an accessible subcutaneous melanoma metastasis.
Age
21 - 70 years
Sex
ALL
Healthy Volunteers
No
Melanoma Unit, Mater Misericordiae Hospital
Newcastle, New South Wales, Australia
Start Date
November 8, 2005
Primary Completion Date
April 21, 2006
Completion Date
April 21, 2006
Last Updated
June 27, 2019
3
ACTUAL participants
Coxsackievirus A21
DRUG
Lead Sponsor
Viralytics
NCT07371663
NCT01898039
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06209580